Bactana Corp.

Bactana Corp. , based in the US, specializes in developing innovative health solutions targeting intestinal and metabolic health through its unique probiotics and postbiotics offerings. Bactana Corp. focuses on health innovations by developing unique solutions for gut and metabolic health.

Established in 2016 in Farmington, US, the company has received funding from various investors including Connecticut Innovations and Cornell University Endowment. Rodrigo Bicalho founded the company, which has completed four deals, with the most recent funding round on May 13, 2025, raising USD 1. 3 mn led by Connecticut Innovations. Bactana specializes in the development and production of innovative health solutions primarily targeting intestinal and metabolic health through its unique offerings of probiotics and postbiotics.

The company’s core product line includes patented formulations derived from small molecules isolated from proprietary anaerobic cell lines, designed to facilitate the health of both animals and humans. Their flagship product, Pawsni™ Metabolic Health, serves as a therapeutic supplement aimed at pets, addressing metabolic conditions and digestive disorders. Bactana's products are distributed in various geographical markets, including North America and Canada, where they cater to veterinarians, pet owners, and livestock producers seeking alternatives to traditional antibiotics. The company is positioned within the rapidly growing sector of health supplements, focusing on improving overall well-being through scientifically validated solutions.

Bactana generates revenue through direct sales of its innovative health solutions, particularly its core product offerings like Pawsni™ Metabolic Health. The company engages in B2B transactions with veterinary clinics, pet retailers, and livestock producers, establishing partnerships that facilitate the distribution of their products. Transactions typically involve wholesale agreements where retailers purchase products in bulk to resell to end consumers, encapsulating a structured pricing model that reflects the premium nature of the formulations. While specific pricing details for individual products are not disclosed, the company’s approach emphasizes building long-term relationships with its client base, which includes veterinarians and health-conscious pet owners.

Through these partnerships, Bactana aims to leverage its patented technology to capture a significant share of the health supplement market focused on animal welfare and metabolic health. On May 13, 2025, Kemin Industries Inc. agreed to acquire Bactana Corp. The acquisition aims to enable Kemin Industries to venture into emerging technologies that improve gut health in pets and other animals.

This strategic move will likely support Bactana’s plans for expanding its product offerings and distribution channels in new geographic markets.